Hypertension Treatment in Blacks: Discussion of the U.S. Clinical Practice Guidelines

Stephen K. Williams, Joseph Ravenell, Sara Seyedali, Sam Nayef, Gbenga Ogedegbe

Research output: Contribution to journalReview article

Abstract

Blacks are especially susceptible to hypertension (HTN) and its associated organ damage leading to adverse cardiovascular, cerebrovascular and renal outcomes. Accordingly, HTN is particularly significant in contributing to the black-white racial differences in health outcomes in the US. As such, in order to address these health disparities, practical clinical practice guidelines (CPGs) on how to treat HTN, specifically in blacks, are needed. This review article is a timely addition to the literature because the most recent U.S. CPG more explicitly emphasizes race into the algorithmic management of HTN. However, recent clinical research cautions that use of race as a proxy to determine therapeutic response to pharmaceutical agents may be erroneous. This review will address the implications of the use of race in the hypertension CPGs. We will review the rationale behind the introduction of race into the U.S. CPG and the level of evidence that was available to justify this introduction. Finally, we will conclude with practical considerations in the treatment of HTN in blacks.

Original languageEnglish (US)
Pages (from-to)282-288
Number of pages7
JournalProgress in Cardiovascular Diseases
Volume59
Issue number3
DOIs
StatePublished - Nov 1 2016

Fingerprint

Practice Guidelines
Hypertension
Therapeutics
Health
Proxy
Kidney
Research
Pharmaceutical Preparations

Keywords

  • African Americans
  • Blacks
  • Hypertension
  • Minorities

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Hypertension Treatment in Blacks : Discussion of the U.S. Clinical Practice Guidelines. / Williams, Stephen K.; Ravenell, Joseph; Seyedali, Sara; Nayef, Sam; Ogedegbe, Gbenga.

In: Progress in Cardiovascular Diseases, Vol. 59, No. 3, 01.11.2016, p. 282-288.

Research output: Contribution to journalReview article

Williams, Stephen K. ; Ravenell, Joseph ; Seyedali, Sara ; Nayef, Sam ; Ogedegbe, Gbenga. / Hypertension Treatment in Blacks : Discussion of the U.S. Clinical Practice Guidelines. In: Progress in Cardiovascular Diseases. 2016 ; Vol. 59, No. 3. pp. 282-288.
@article{8564756307b44f06975aec149a80603f,
title = "Hypertension Treatment in Blacks: Discussion of the U.S. Clinical Practice Guidelines",
abstract = "Blacks are especially susceptible to hypertension (HTN) and its associated organ damage leading to adverse cardiovascular, cerebrovascular and renal outcomes. Accordingly, HTN is particularly significant in contributing to the black-white racial differences in health outcomes in the US. As such, in order to address these health disparities, practical clinical practice guidelines (CPGs) on how to treat HTN, specifically in blacks, are needed. This review article is a timely addition to the literature because the most recent U.S. CPG more explicitly emphasizes race into the algorithmic management of HTN. However, recent clinical research cautions that use of race as a proxy to determine therapeutic response to pharmaceutical agents may be erroneous. This review will address the implications of the use of race in the hypertension CPGs. We will review the rationale behind the introduction of race into the U.S. CPG and the level of evidence that was available to justify this introduction. Finally, we will conclude with practical considerations in the treatment of HTN in blacks.",
keywords = "African Americans, Blacks, Hypertension, Minorities",
author = "Williams, {Stephen K.} and Joseph Ravenell and Sara Seyedali and Sam Nayef and Gbenga Ogedegbe",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.pcad.2016.09.004",
language = "English (US)",
volume = "59",
pages = "282--288",
journal = "Progress in Cardiovascular Diseases",
issn = "0033-0620",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Hypertension Treatment in Blacks

T2 - Discussion of the U.S. Clinical Practice Guidelines

AU - Williams, Stephen K.

AU - Ravenell, Joseph

AU - Seyedali, Sara

AU - Nayef, Sam

AU - Ogedegbe, Gbenga

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Blacks are especially susceptible to hypertension (HTN) and its associated organ damage leading to adverse cardiovascular, cerebrovascular and renal outcomes. Accordingly, HTN is particularly significant in contributing to the black-white racial differences in health outcomes in the US. As such, in order to address these health disparities, practical clinical practice guidelines (CPGs) on how to treat HTN, specifically in blacks, are needed. This review article is a timely addition to the literature because the most recent U.S. CPG more explicitly emphasizes race into the algorithmic management of HTN. However, recent clinical research cautions that use of race as a proxy to determine therapeutic response to pharmaceutical agents may be erroneous. This review will address the implications of the use of race in the hypertension CPGs. We will review the rationale behind the introduction of race into the U.S. CPG and the level of evidence that was available to justify this introduction. Finally, we will conclude with practical considerations in the treatment of HTN in blacks.

AB - Blacks are especially susceptible to hypertension (HTN) and its associated organ damage leading to adverse cardiovascular, cerebrovascular and renal outcomes. Accordingly, HTN is particularly significant in contributing to the black-white racial differences in health outcomes in the US. As such, in order to address these health disparities, practical clinical practice guidelines (CPGs) on how to treat HTN, specifically in blacks, are needed. This review article is a timely addition to the literature because the most recent U.S. CPG more explicitly emphasizes race into the algorithmic management of HTN. However, recent clinical research cautions that use of race as a proxy to determine therapeutic response to pharmaceutical agents may be erroneous. This review will address the implications of the use of race in the hypertension CPGs. We will review the rationale behind the introduction of race into the U.S. CPG and the level of evidence that was available to justify this introduction. Finally, we will conclude with practical considerations in the treatment of HTN in blacks.

KW - African Americans

KW - Blacks

KW - Hypertension

KW - Minorities

UR - http://www.scopus.com/inward/record.url?scp=85003955385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003955385&partnerID=8YFLogxK

U2 - 10.1016/j.pcad.2016.09.004

DO - 10.1016/j.pcad.2016.09.004

M3 - Review article

C2 - 27693861

AN - SCOPUS:85003955385

VL - 59

SP - 282

EP - 288

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

SN - 0033-0620

IS - 3

ER -